+++
title = "Abel De La Rosa, Ph.D."
slug = "abel-de-la-rosa"
bgImage = "/img/leadership/abel-de-la-rosa.jpg"
type = "leadership"
weight = "1"
position = ""
layout = "directors"
+++


Dr. De La Rosa is the Chief Executive Officer and a co-founder of Antios Therapeutics. He was most recently the Chief Scientific Officer of the Drug Innovation Ventures at Emory (DRIVE) and the Emory Institute for Drug Development (EIDD), focused on the discovery and development of antiviral drugs for the treatment of viral diseases of unmet medical need and global concern. During his nearly 6-year tenure at Emory University, he helped raise over $40 million in funding and was a co-inventor on technologies licensed to AbbVie and Antios Therapeutics.

Prior to joining Emory University, Dr. De La Rosa was Senior Vice President of Business Development & Scientific Affairs at Pharmasset. From 2002 until its acquisition by Gilead Sciences (NASDAQ: GILD) for $11 billion in 2012, he was responsible for licensing, strategic transactions, and alliance management of collaborations and partnerships with pharmaceutical companies and universities. He provided business and scientific leadership to drug development programs for the treatment of HIV, Hepatitis B and Hepatitis C, including Sofosbuvir. Prior to Pharmasset, Dr. De La Rosa held both scientific and business positions at Visible Genetics, where he was responsible for the development and improvement of genotyping tests for HIV, Hepatitis B and Hepatitis C, including the first sequencing-based HIV drug resistance test to receive FDA approval. He also held scientific positions at Innogenetics, Boston Biomedica, and Digene, developing molecular diagnostic tests for infectious diseases. He is an inventor and author on several U.S. patents and publications relating to molecular diagnostic methods, techniques and therapeutics for infectious diseases and cancer.

Dr. De La Rosa has served on Scientific Advisory Boards and Board of Directors of biotechnology companies. He currently serves on the Board of Directors of Celtaxys.

Dr. De La Rosa earned a Fogarty Fellowship and an Intramural Research Training Award Fellowship from the National Institutes of Health, where he completed post-doctoral training in the Laboratory of Biochemistry and the Laboratory of Pathology of the National Cancer Institute. He holds a Bachelor's Degree in Microbiology from the University of California, San Diego, and a Ph.D. in Microbiology from Miami University.